Boston Properties Inc. (BXP) has been given the green light to proceed with construction of AstraZeneca’s Kendall Square lab tower, despite objections from Brammer Bio Inc. According to a ruling by Suffolk County Superior Court Judge Kenneth Salinger, the ongoing construction at 290 Binney St. will not impede access to Brammer’s loading docks at 250 Binney St., thus rejecting their request for a project halt.
In response to Thermo Fisher subsidiary Brammer’s claims that the construction would disrupt operations and violate their sublease, Judge Salinger found no evidence supporting these allegations. He noted that BXP holds an easement allowing roadway reconfiguration and partial tower development on the disputed property.
Thermo Fisher has expressed strong disagreement with this ruling and is currently exploring legal options in response. The lawsuit also includes accusations of trespassing and operational disruptions caused by ongoing construction activities; however, Judge Salinger found no basis for these claims as BXP had taken measures to minimize inconvenience during this process.
The judge also upheld the validity of a recent easement change made by a BXP affiliate in order facilitate smooth progress on this project. Despite Thermo Fisher’s disagreement with this decision, they are considering potential legal actions moving forward.
This article was originally published on Connect CRE.
